Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295310 | 0.88 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2MAPTRXFP1NPSR1 | |
| SCHEMBL2954111 | 0.83 | MAPT (0.62) | ALDH1A1SMN1; SMN2POLBMAPTRXFP1 | |
| SCHEMBL4293880 | 0.82 | ALDH1A1 (0.68) | ALDH1A1SMN1; SMN2MAPTRXFP1NPSR1 | |
| SCHEMBL4295545 | 0.82 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MAPTRXFP1NPSR1 | |
| SCHEMBL10652999 | 0.81 | MAPT (0.78) | ALDH1A1SMN1; SMN2POLBMAPTRXFP1 | |
| SCHEMBL4724873 | 0.80 | ALDH1A1 (0.73) | ALDH1A1POLBMAPTRXFP1GAA | |
| SCHEMBL29195060 | 0.79 | MAPT (0.75) | ALDH1A1SMN1; SMN2POLBMAPTRXFP1 | |
| SCHEMBL7339238 | 0.78 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2POLBMAPTRXFP1 | |
| SCHEMBL4290795 | 0.78 | FNTA (0.57) | ALDH1A1SMN1; SMN2POLBMAPTRXFP1 | |
| SCHEMBL4290793 | 0.78 | FNTA (0.57) | ALDH1A1SMN1; SMN2POLBMAPTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| EP-1971596-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | Takeda Pharmaceutical Company Limited (JP) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | ALDH1A1 2708/4885SMN1; SMN2 4585/4885POLB 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.